DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 366,400 shares, an increase of 38.7% from the March 15th total of 264,200 shares. Currently, 0.9% of the company’s stock are short sold. Based on an average daily trading volume, of 90,200 shares, the short-interest ratio is currently 4.1 days.

DiaMedica Therapeutics Stock Performance

DMAC traded up $0.07 during trading hours on Friday, reaching $3.54. The company’s stock had a trading volume of 46,109 shares, compared to its average volume of 73,627. The company’s 50-day moving average is $5.05 and its 200-day moving average is $5.05. DiaMedica Therapeutics has a 52 week low of $2.14 and a 52 week high of $6.82. The firm has a market cap of $151.71 million, a PE ratio of -6.32 and a beta of 1.50.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Equities analysts anticipate that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Susquehanna International Group LLP lifted its holdings in DiaMedica Therapeutics by 269.5% during the 4th quarter. Susquehanna International Group LLP now owns 374,845 shares of the company’s stock worth $2,035,000 after purchasing an additional 273,395 shares during the last quarter. 683 Capital Management LLC bought a new stake in shares of DiaMedica Therapeutics in the fourth quarter valued at about $413,000. Geode Capital Management LLC grew its stake in shares of DiaMedica Therapeutics by 29.6% in the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock valued at $1,286,000 after acquiring an additional 70,070 shares in the last quarter. Northern Trust Corp increased its position in DiaMedica Therapeutics by 49.8% during the fourth quarter. Northern Trust Corp now owns 180,192 shares of the company’s stock worth $978,000 after acquiring an additional 59,902 shares during the period. Finally, Millennium Management LLC raised its stake in DiaMedica Therapeutics by 151.8% in the 4th quarter. Millennium Management LLC now owns 84,829 shares of the company’s stock worth $461,000 after purchasing an additional 51,139 shares in the last quarter. 10.12% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright boosted their price objective on shares of DiaMedica Therapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, March 19th.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.